Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06799247 · ClinicalTrials.gov registry record · Phase 3

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

A Phase 3 study of Myasthaenia Gravis, sponsored by Cartesian Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
100
Enrollment target
20
Study locations

NCT06799247 is a Phase 3 study of Myasthaenia Gravis that is actively recruiting participants, run by Cartesian Therapeutics. The registered enrollment target is 100 participants. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06799247, a Phase 3 study of Myasthaenia Gravis, is actively recruiting participants, sponsored by Cartesian Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.

Conditions Studied

Interventions

  • BIOLOGICAL Decartes-08
  • OTHER Placebo Drug

Study Locations (20)

California

  • A13 - Carlsbad
  • A14 - Orange

Florida

  • A48 - Maitland
  • A10 - Tampa

New York

  • A12 - Amherst
  • A47 - New York

North Carolina

  • A22 - Chapel Hill
  • A39 - Charlotte

Pennsylvania

  • A11 - Philadelphia
  • A49 - Pittsburgh

Other

  • A23 - Rome
  • A30 - Krakow

Arizona

  • A40 - Tucson

Colorado

  • A21 - Aurora

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-05-06
Est. Completion 2027-09-30
Phase Phase 3

Sponsor

Cartesian Therapeutics

12 total trials

What the Registry Record Tells You About NCT06799247

The ClinicalTrials.gov registry entry for NCT06799247 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myasthaenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Decartes-08 is the first listed.

NCT06799247 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT06799247 about?

NCT06799247 is a clinical study titled "Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis". The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participan...

What is the current status of trial NCT06799247?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2025-05-06. Estimated completion is 2027-09-30.

What conditions does trial NCT06799247 study?

This clinical trial studies the following conditions: Myasthaenia Gravis.

What interventions are being tested in trial NCT06799247?

The interventions under investigation include: Decartes-08 (BIOLOGICAL), Placebo Drug (OTHER).

Who is sponsoring clinical trial NCT06799247?

This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06799247 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myasthaenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.